Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Bio-Path Holdings reports positive Q1 results and advances key drug programs

Bio-Path Holdings (BPTH) showcased progress in key drug programs, financial stability, and global patent expansion. While facing regulatory and competitive challenges, the company is well-positioned to capitalize on opportunities in the biopharmaceutical sector. Optimism for future growth and innovation was expressed by CEO Peter Nielsen during the earnings call.

Bio-Path reports Q2 progress with prexigebersen and promising trials

Bio-Path Holdings showcased progress in clinical trials and financial management, emphasizing innovation and commitment to revolutionize cancer treatment.
While facing challenges in commercialization and market competition, the company's strong dedication to personalized medicine and promising trial results present growth opportunities.
With a focus on leveraging molecular biomarkers and advancing pipeline candidates, Bio-Path is strategically positioned to drive future success in the oncology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen Peer Reviewed Manuscript Highlights Challenges of Antisense Oligonucleotide Drug Delivery and Benefits of Prexigebersen

Bio-Path Announces Publication in Biomedicines

ACADIA Pharma

Cidara Therapeutics

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejection: Acadia said the FDA has issued a complete response letter regarding its supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis.

Why Acadia Pharma, Bio-path And Cidara Are Moving Today

The stock price of Bio-Path Holdings Inc (NASDAQ: BPTH) has increased by over 15% pre-market. This is why it happened.

Bio-Path Stock Price Increased Over 15% Pre-Market: Why It Happened

Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapies, decitabine and venetoclax. The safety run-in comprised six evaluable patients.

Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen (BP1001), a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia (AML) patients. The safety run-in of Stage 2 of the Phase 2 clinical trial was comprised of six evaluable patients who were treated with the triple combination of prexigebersen, decitabine and venetoclax.

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bio-Path (BPTH) Moves to Buy: Rationale Behind the Upgrade

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15 and May 17-21, 2021.

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

Nielsen Hlds

Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q4 2020 Results - Earnings Call Transcript

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Reports Full Year 2020 Financial Results

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, March 10, 2021 at 8:30 a.m. ET to report financial results for the year ended December 31, 2020 and to provide a business overview.

Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021

HOUSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced public offering for the offering of 1,710,600 shares of common stock at a price to the public of $7.60 per share, for aggregate gross proceeds to the Company of approximately $13.0 million, before deducting the fees and estimated offering expenses payable by the Company.

Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of its previously announced public offering for the offering of 1,710,600 shares of common stock at a price to the public of $7.60 per share, for aggregate gross proceeds to the Company of approximately $13.0 million, before deducting the fees and estimated offering expenses payable by the Company. The offering is expected to close on or about February 18, 2021, subject to customary closing conditions.

Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

Bio-Path (NASDAQ: BPTH) shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company.

Why Bio-Path's Stock Is Surging Higher Today

Bio-Path Holdings (BPTH) stock is rocketing higher on Wednesday after announcing patent updates for its DNAbilize platform. The post BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today appeared first on InvestorPlace.

BPTH Stock: Why Bio-Path Holdings Is Skyrocketing 200% Today

The stock price of Bio-Path Holdings Inc (NASDAQ: BPTH) is trading at over 80% pre-market. This is why it happened.

BPTH Stock Price Increases Over 80% Pre-Market: Why It Happened

Provides Expanded Protection to Seminal Patents Related to DNAbilize Provides Expanded Protection to Seminal Patents Related to DNAbilize

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology

Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call Transcript

Bio-Path Holdings Reports Third Quarter 2020 Financial Results

HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 13, 2020 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2020 and to provide a business overview.

Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

BPTH stock received a boost on Thursday after Bio-Path received a notice of allowance for a strategic patent for its candidate Prexigebersen. The post Bio-Path Holdings News: Why BPTH Stock Is Soaring Today appeared first on InvestorPlace.

Bio-Path Holdings News: Why BPTH Stock Is Soaring Today

Growing Patent Estate Creates Value and Supports Key Combination Therapies Growing Patent Estate Creates Value and Supports Key Combination Therapies

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

HOUSTON, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:30 a.m. ET.

Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Bio-Path Holdings Stock (BPTH)